Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Fleming

Showing results (421-430 of 437) with videos related to

Pageof 44
Sort By:
The Science of the Total Environment|December 19, 2024
The risk of high-biomass HABs: Triggers and dynamics of a non-toxic bloom of Prorocentrum micans in Chilean PatagoniaPatricio A Díaz, Leila Basti, Iván Pérez-Santos, et al.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Cancer Cell|January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Cancer Cell|June 12, 2019
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 21, 2026
The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndromeJulianne G Clina, Brian C Helsel, Sigan L Hartley, et al.
Journal of Oncology Practice|July 2, 2013
Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessmentHoward A Zaren, Suresh Nair, Ronald S Go, et al.
Scientific Reports|August 1, 2023
TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathwaysKarnika Singh, Chunhua Han, Jessica L Fleming, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
Obesity (Silver Spring, Md.)|June 5, 2026
Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down SyndromeVictoria L Fleming-Batayneh, Brian C Helsel, Lauren T Ptomey, et al.
Elife|March 26, 2025
Network segregation is associated with processing speed in the cognitively healthy oldest-oldSara A Nolin, Mary E Faulkner, Paul Stewart, et al.
Pageof 44

Showing results (421-430 of 437) with videos related to

Sort By:
Pageof 44
The Science of the Total Environment|December 19, 2024
The risk of high-biomass HABs: Triggers and dynamics of a non-toxic bloom of Prorocentrum micans in Chilean PatagoniaPatricio A Díaz, Leila Basti, Iván Pérez-Santos, et al.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Cancer Cell|January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Cancer Cell|June 12, 2019
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 21, 2026
The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndromeJulianne G Clina, Brian C Helsel, Sigan L Hartley, et al.
Journal of Oncology Practice|July 2, 2013
Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessmentHoward A Zaren, Suresh Nair, Ronald S Go, et al.
Scientific Reports|August 1, 2023
TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathwaysKarnika Singh, Chunhua Han, Jessica L Fleming, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
Obesity (Silver Spring, Md.)|June 5, 2026
Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down SyndromeVictoria L Fleming-Batayneh, Brian C Helsel, Lauren T Ptomey, et al.
Elife|March 26, 2025
Network segregation is associated with processing speed in the cognitively healthy oldest-oldSara A Nolin, Mary E Faulkner, Paul Stewart, et al.
Pageof 44